<DOC>
	<DOCNO>NCT01099722</DOCNO>
	<brief_summary>A comparator study assess safety efficacy Flutiform® compare symbicort turbohaler asthma patient moderate severe persistent , reversible asthma .</brief_summary>
	<brief_title>Assessment Efficacy Safety FlutiForm® pMDI 125/5 µg ( 2 Puffs Bid ) Versus Symbicort® Turbohaler® 200/6 µg ( 2 Puffs Bid ) Adolescent Adult Subjects With Moderate Severe Persistent , Reversible Asthma</brief_title>
	<detailed_description>This study involve 2-4 week run-in phase follow 12 week double blind treatment phase . During run-in phase , subject receive Flixotide® . In treatment phase subject randomise one two treatment group receive either FlutiForm® placebo inhaler symbicort® turbohaler® symbicort® turbohaler® placebo inhaler Flutiform ® . Efficacy assess lung function test , asthma symptom , sleep disturbance due asthma rescue medication use . Safety assess adverse event , lab test , ECGs vital sign .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>1 . Male female subject least 12 year old 2 . Female subject less 1 year postmenopausal must negative urine pregnancy test record screen visit prior first dose study medication , nonlactating , &amp; willing use adequate &amp; highly effective method contraception throughout study . A highly effective method birth control define result low failure rate ( i.e. , less 1 % per year ) use consistently &amp; correctly sterilisation , implant , injectables , combine oral contraceptive , IUDs ( Intrauterine Device , hormonal ) , sexual abstinence vasectomise partner . 3 . Known history moderate severe persistent , reversible asthma ≥ 6 month prior Screening Visit characterise : Treatment inhaled corticosteroid ( ICS ) dose 250 1000 µg fluticasone equivalent OR Treatment wth ICS dose 200500 µg fluticasone equivalent combination Long Acting β2Agonist ( LABA ) . 4 . Demonstrated FEV1 ≥ 50 % ≤ 80 % predict normal value ( Quanjer et al. , 1993 ( adult ) , &amp; 1995 ( adolescent ) ) Screening Period ( Visit 1 Visit 2 ) follow appropriate withhold asthma medication ( applicable ) . No β2agonist use day test No use inhale combination asthma therapy day test . Inhaled corticosteroid allow day test . 5 . Documented reversibility ≥ 15 % FEV1 visit 1 visit 2 . 6 . Demonstrated satisfactory technique use study medication i.e . pMDI Dry Powder Inhaler ( DPI ) device . 7 . Willing &amp; able enter information electronic diary &amp; attend study visit . 8 . Willing &amp; able substitute study medication pre study prescribe asthma medication duration study . 9 . Written inform consent obtain . Inclusion criterion require follow runin : Subject use rescue medication least 3 day &amp; least 1 night sleep disturbance ( i.e. , sleep disturbance score ≥ 1 ) last 7 day run period , OR subject use rescue medication least 3 day &amp; least 3 day asthma symptom ( i.e. , symptom score ≥ 1 ) last 7 day runin period . Exclusion criterion : 1 . Near fatal lifethreatening ( include intubation ) asthma within past year . 2 . Hospitalisation emergency visit asthma within 4 week Screening Visit . 3 . Known history systemic ( injectable oral ) corticosteroid medication use within 1 month Screening Visit . 4 . Known history omalizumab use within past 6 month . 5 . Current evidence know history clinically significant disease abnormality include uncontrolled coronary artery disease , congestive heart failure , myocardial infarction , cardiac dysrhythmia . 'Clinically significant ' defined disease , opinion Investigator , would put subject risk study participation , would affect outcome study . 6 . In investigator 's opinion clinically significant upper low respiratory infection within 4 week prior Screening Visit . 7 . Significant , nonreversible , active pulmonary disease ( e.g. , chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , bronchiectasis , tuberculosis ) . 8 . Known Human Immunodeficiency Virus ( HIV ) positive status . 9 . Subject smoke history equivalent `` 10 pack year '' ( i.e. , least 1 pack 20 cigarettes/day 10 year 10 packs/day 1 year , etc. ) . 10 . Current smoke history within 12 month prior Screening Visit . 11 . Current evidence know history alcohol and/or substance abuse within 12 month prior Screening Visit . 12 . Subject take Bblocking agent , tricyclic antidepressant , monoamine oxidase inhibitor , astemizole ( Hismanal ) , quinidine type antiarrhythmic , potent CYP 3A4 inhibitor ketoconazole within past week . 13 . Current use medication allow protocol effect bronchospasm &amp; /or pulmonary function . 14 . Current evidence know history hypersensitivity idiosyncratic reaction test medication component . 15 . Subject receive investigational drug within 30 day Screening Visit ( 12 week oral injectable steroid ) . 16 . Subject currently participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>moderate severe persistent reversible asthma</keyword>
</DOC>